Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 4, 2004 - Issue 6
Submit an article Journal homepage
43
Views
8
CrossRef citations to date
0
Altmetric
Review

Management of muscle-invasive bladder cancer in the elderly

Umberto Basso Azienda Ospedale – University, Department of Medical Oncology, Ospedale Busonera, via Gattamelata 64, 35100 Padova, Italy. [email protected]
,
Pierfrancesco Bassi Azienda Ospedale – University, Department of Urology, Via Giustiniani 2, 35100 Padova, Italy. [email protected]
&
Silvio Monfardini Azienda Ospedale – University, Department of Medical Oncology, Ospedale Busonera, via Gattamelata 64, 35100 Padova, Italy. [email protected]
Pages 1017-1035 | Published online: 10 Jan 2014

References

  • Sant M, Aareleid T, Berrino F et al. EUROCARE-3: survival of cancer patients diagnosed 1990–1994: results and commentary. Ann. Oncol. 14 (Suppl. 5), V61—V118 (2003).
  • •Updated cancer survival rates in the EUROCARE consortium, showing an absolute 10% reduction in 5-year survival probability in elderly patients compared with younger individuals.
  • Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl. J. Med. 341,2061-2067 (1999).
  • Sternberg CN, de Mulder PHM, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity M-VAC chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic M-VAC in advanced urothelial tract tumors: EORTC protocol No. 30924. Clin. Oncol. 19, 2638–2646 (2001).
  • •Prophylactic granulocyte colony-stimulating factor (GCSF) allows administration of intensified methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) with reduced hematologic toxicities, increased complete response rate and favorable trend for prolonged survival.
  • Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Grit. Rev. Oncol. Hernatol. 39,219–226 (2001).
  • •Updated epidemiologic analysis of trends in cancer incidence and mortality in the elderly.
  • Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancerj Clin. 52,23–47 (2002).
  • Mandeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol. Oncol. 22, 86–92 (2004).
  • Mungan NA, Aben KK, Schoenberg MP eta]. Gender differences in stage-adjusted bladder cancer survival. Urology55, 876–880 (2000).
  • Linn JF, Sesterhann I, Mostofi FK et al. The molecular characteristics of bladder cancer in young patients. J Urol. 159, 1493–1496 (1998).
  • Bornman DM, Mathew S, Alsruhe J et al. Methylation of the E-cadherin gene in bladder neoplasm and in normal urothelial epithelium from elderly individuals. Am. J Pathol. 159,831–835 (2001).
  • Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt) 14, 221–227 (2000) .
  • •Detailed review on aims and methods of geriatric oncology.
  • Terret C. Management and geriatric assessment of cancer in the elderly. Expert. Rev. Anticancer. Ther. 4,469–475 (2004).
  • •Discussion on most promising avenues of research and future challenges in the field of geriatric oncology.
  • Sanchez-Ortiz RF, Huang WC, Mick R et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol. 169,110-115 (2003).
  • Monfardini S, Balducci L. A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly. Eur. Cancer35, 1771–1772 (1999).
  • •Contains keen argumentation for the use of multidimensional geriatric assessment (MGA) in the management of elderly cancer patients.
  • Extermann M. Measuring comorbidity in older cancer patients. Eur. J Cancer. 36, 453–471 (2000).
  • •Detailed discussion on methods and scales to be used for correct evaluation of comorbidities in elderly cancer patients.
  • Miller DC, Taub DA, Dunn RL eta]. The impact of comorbid disease on cancer control and survival following radical cystectomy. I Uml. 169,105–109 (2003).
  • •Retrospective analysis linking comorbidity with outcome after cystectomy for bladder cancer (BC).
  • Solsona E, Iborra I, Ricos JV et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow-up of a prospective study. J Urol. 159,95–99 (1998).
  • Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10 year outcome.Oncol. 19,89–93(2001).
  • Stein JP, Liesskowsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin. Oncol. 19, 666–675 (2001).
  • •Largest retrospective series of cystectomy published so far, reporting an overall 5- and 10-year survival of 66 and 43%, respectively. Nonorgan-confined disease (pT3b—pT4), lymph node involvement and inadequate lymphadenectomy are the strongest adverse prognostic factors.
  • Gschwend JE, Fair WR, Vieweg J. Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies. Eur. Urol. 38, 121–130 (2000).
  • Bassi P. Outcome of radical cystectomy for invasive bladder cancer. Carr. Opin. Urol. 10,459–63 (2000).
  • •Appraisal of the outcome and morbidity of cystectomy in recent years.
  • Bassi P, Ferrante GD, Piazza N et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. 1 Urol. 161,1494-1497 (1999).
  • Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today: a homogeneous series without neoadjuvant therapy. JOncol. 21,690–696 (2003).
  • Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a co-operative group report. 1 Clin. Oncol 22,2781–2789 (2004).
  • •Recent analysis of surgical variables in patients enrolled in the Southwest Oncology Group (SWOG) Intergroup randomized trial demonstrating that positive margins after cystectomy and less than ten lymph nodes removed correlate with shorter disease-free and overall survival.
  • Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB and p16 expression predict clinical outcome in cystectomy with bladder cancer. JOncol. 22, 1014–1024 (2004).
  • •Interesting analysis of molecular prognostic factors for BC demonstrating that p53-positive staining has the strongest relevance, followed by p2 1.
  • Hussain SA, James N. Organ preservation strategies in bladder cancer. Expert. Rev. Anticancer. Ther. 2,641–649 (2002).
  • •Detailed discussion on pros and cons of bladder-sparing strategies, which have yet to be compared objectively with cystectomy in randomized trials.
  • Lehmann J, Retz M, Siemer S eta]. Managing locally advanced bladder cancer. Expert Rev. Anticancer. Ther. 2, 656–666 (2004).
  • Dahm P, Tuttle-Newhall J, Nimjee SM eta]. Indications for admission to the surgical intensive care unit after radical cystectomy and urinary diversion. J Urol. 166,189–193 (2001).
  • Figueroa A, Stein JP, Dickinson M, Skinner EC, Thanghaturai D, Michail MS eta]. Radical cystectomy for elderly patients with bladder carcinoma. Cancer 83, 141–147 (1998).
  • ••Largest series of elderly patientsundergoing cystectomy published so far, reporting that, upon proper selection, comparable results with younger patients both in terms of disease control and perioperative mortality and morbidity can be obtained in patients of 70 years of age or above.
  • Chang SS, Alberts G, Cookson MS et al. Radical cystectomy is safe in elderly patients with high risk. J Urol. 166, 938–941 (2001).
  • Game X, Soulib M, Seguin P et al. Radical cystectomy in patients older than 75 years: assessment of morbidity and mortality. Eur. Urol. 39,525-529 (2001).
  • Saika T, Suyama B, Murata T eta]. Orthotopic neobladder reconstruction in elderly bladder cancer patients Int. J Urol. 8,533–538 (2001).
  • Soulie M, Straub M, Game X eta]. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol. 167, 1325–1328 (2002).
  • Malavaud B, Vaessen C, Mouzin M eta]. Complications for radical cystectomy. Eur. Urn]. 39,79–84 (2001).
  • Lance RS, Grossman HB. Cystectomy in the elderly. Sern. Uro1 Onco1 19,51–55 (2001).
  • •Provocative attempt to set the age limit at which the survival benefit of cystectomy is counterbalanced by the risk of dying from other causes.
  • Holmang S, Hedelin H, Borghede G eta]. Long-term follow-up of a bladder carcinoma cohort: questionable value of radical radiotherapy J Urol. 157, 1642–1646 (1997).
  • Sengelov L, Klintorp S, Havesteen H et al. Treatment outcome following radiotherapy in elderly patients with bladder cancer Radiother. Onco1 44,53–58 (1997).
  • McLaren DB, Morrey D, Mason MD. Hypo-fractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother. Oncol. 43,171–174 (1997).
  • Rostom AY, Tahir S, Gershuny AR et al. Once weekly irradiation for carcinoma of the bladder. Int. J Radiat. Onco1 Biol. Phys. 35,289-292 (1996).
  • Shelley MD, Wilt TJ, Barber J et al. A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice? Clin. Oncol. 16,166–171 (2004).
  • Scrimger RA, Murtha AD, Parliament MB et al. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors. Int. J Radiat. Onco1 Biol. Phys. 51,23-30 (2001).
  • Del Muro XG, Condom E, Vigubs F et al. P53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100, 1859–1867 (2004).
  • Coppin CML, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation.j Clin. Onco1 11,2901–2907 (1996).
  • Shipley WU, Kaufman DS, Sehr E et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology60, 62–67 (2002).
  • Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. j Clin. Onco120, 3061–3071 (2002).
  • Hussain SA, Stocken DD, Peake DR eta]. Long-term results of a Phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br.Cancer 90,2106–2111 (2004).
  • Arias F, Duenas M, Maritnez E et al. Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle. Cancer 80(1), 115–120 (1997).
  • Coffin JR, Rajan R, Souhami L. Tolerance of radiotherapy and chemotherapy in elderly patient with bladder cancer. Am. J Clin. Onco1 27,172–177 (2004).
  • Sangar VK, Cowan R, Margison GP et al. An evaluation of gemcitabine differential radiosensitising effect in related bladder cancer cell lines. Br. Cancer 90,542–548 (2004).
  • Caffo O, Fellin G, Graffer U et al. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int. J Radiother. Onco1 Biol. Phys. 57, 1310–1316 (2003).
  • Kent E, Sandler H, Montie J et al. Combined modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a Phase I trial. JOnco1 22,2540–2545(2004).
  • Herman JM, Smith DC, Montie J et al. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology64, 69–73 (2004).
  • Raghavan D, Quinn D, Skinner DG et al. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg. Oncol. 11, 55–63 (2002).
  • Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361,1927–1934 (2003).
  • •• Pivotal meta-analysis demonstrating a 13% relative reduction in the risk of death with platinum-based polychemotherapy administered before surgery or radiotherapy, a benefit that was found to be independent of age and stage.
  • Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng1 J Med. 349,859-866 (2003).
  • •Large SWOG 8710—Intergroup 0080 trial comparing three neoadjuvant MVAC cycles before cystectomy against cystectomy alone, reporting a huge increase in overall survival (31 months) at borderline statistical significance (p = 0.06).
  • Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomised trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M- VAC. JOncol. 19,4005–4013(2000.
  • •Randomized trial which did not find a survival difference when both neoadjuvant and adjuvant chemotherapy with MVAC was administered compared with an equal number of adjuvant only cycles.
  • Sternberg CN, Pansadoro V, Calabro F et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97,1644–1652 (2003).
  • •Contains a subgroup analysis of patients older than 70 years treated with MVAC, in which frequent dose reductions and comparable toxicities with younger patients are reported.
  • Chester JD, Hall GD, Forster M eta]. Systemic chemotherapy for patients with bladder cancer — current controversies and future directions. Cancer Treat. Rev. 30, 342–358 (2004).
  • •Detailed review of cytotoxic and non-cytotoxic therapeutic options for BC, with curative (neoadjuvant/adjuvant) or palliative (metastatic) intent.
  • Fossa SD, Sternberg C, Scher HI eta]. Survival of patient with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br. Cancer74, 1655–1659 (1996).
  • Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Onco1 17,3173–3181 (1999).
  • •Retrospective analysis demonstrating that poor performance status and visceral metastases are the two most relevant adverse prognostic factors for patients with advanced or metastatic BC treated with platinum-based chemotherapy.
  • Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a co-operative group study. JOncol. 15,2564–2569, (1997).
  • von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. JOncol. 18, 3068–3077 (2000).
  • ••In this randomized study, the gemcitabineplus carboplatin (GC) regimen did not prove superior to MVAC in terms of response rate, number of toxic deaths and survival, but was better tolerated and was associated with reduced resource utilization, thus becoming one of the standard regimens for advanced BC.
  • Dreicer R, Manola J, Roth BJ et al. Phase II Study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group study."Oncol. 18, 1058–1061 (2000).
  • Meluch AA, Greco FA, Burris HA et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minni Pearl Cancer Research Network.Oncol 19, 3018–3024(2001).
  • Bellmunt J, Gulllem V, Paz Ares JL et al. Phase I—II study of paclitaxel, cisplatin and gemcitabine in advanced transitional cell carcinoma of the urothelium. Oncol. 18, 3247–3255 (2000).
  • Hussain M, Vaishampayan U, Du W et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Cita Oncol. 19, 2527–2533 (2001).
  • Bajorin DF, McCaffrey JA, Dodd PM et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a Phase II trial evaluating two dosing schedules. Cancer 88, 1671–1678 (2000).
  • Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulation factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: a multicenter randomised, Phase III study from the Hellenic Co-operative Oncology Group. J Cilia. Oncol. 22,220-228 (2004).
  • •A recent randomized comparison of MVAC against a taxane-based regimen, proving that the former is superior in terms of response rate and survival, but causes higher hematologic toxicity notwithstanding the prophylactic use of GCSF in both arms.
  • Dreicer R, Manola J, Roth B et al. ECOG 4897: Phase III trial of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100, 1639–1645 (2004).
  • Bamias A, Ehstathiou E, Hamilos G et al. Outcome of elderly patients following platinum-based chemotherapy for advanced urothelial cancer. Proc. Am. Soc. Clin. Oncol. 23,391 (2004) (Abstract 4542).
  • Roychawdhury DF, Hayden A, Liepa AM. Health-related quality of life parameters as independent prognostic factors in advanced or metastatic bladder cancer. JOncol.21, 673–678 (2003).
  • •Analysis of quality of life parameters in the pivotal MVAC versus GC trial demonstrated the significant role of physical functioning, pain, fatigue and anorexia in predicting worse outcome.
  • Wildiers H, Highley MS, de Bruijn EA et al. Pharmacology of anticancer drugs in the elderly population. Clin. Pharrnacokinet. 42,1213–1242 (2003).
  • ••Detailed review on the pharmacokineticaspects of chemotherapy in the elderly.
  • Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood104, 634–641 (2004).
  • Loehrer PJ Sr, Elson P, Dreicer R et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Co-operative Oncology Group trial. J Cilia. Oncol. 12, 483–488 (1994).
  • Raabe NK, Fossa SD, Paro G. Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. BE j Urol. 64, 604–607 (1989).
  • Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomised Phase II study. Cancer 77, 344–351 (1997).
  • Carteni G, Dogliotti L, Crucitta E et al. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patient (pts) with advanced or metastatic transitional cell carcinoma of the urothelium, (TCCU). Proc. Am. Soc. Clin. Oncol. 22,384 (2003) (Abstract 1543).
  • Cubillo A, Cornide M, Lopez JL et al. Renal tolerance to cisplatin in patients 70 years and older. Am. J Clin. Oncol. 24, 192–197 (2001).
  • •The risk of cisplatin-dependent nephrotoxicity does not appear to be increased in elderly patients due to age.
  • Yamamoto N, Tamura T, Maeda M et al. The influence of aging on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chernother. Pharrnaca 36,102–106 (1995).
  • Nogub-Aliguer M, Cartes J, Arrivi A et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97, 2180–2186 (2003).
  • Vaughn DJ, Manola J, Dreicer R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Co-operative Oncology Group. Cancer 95,1022–1027 (2002).
  • Redman BG, Smith DC, Flaherty L eta]. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.Oncol. 16, 1844–1848(1998).
  • Bellmunt J, de Wit R, Albanell J. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Ear. j Cancer 37, 2212–2215 (2001).
  • Lorusso V, Pollera CF, Antimi M eta]. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Ear. I Cancer34, 1208–1212 (1998).
  • Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J 156, 1606–1608 (1996).
  • •Small trial demonstrating that paclitaxel is well tolerated in BC patients with reduced renal function.
  • Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat. Rev. 30, 333–342 (2004).
  • Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. JOncol. 20,937–940 (2002).
  • Castagneto B, Zai S, Marenco D et al. Single agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology 67(1), 27–32 (2004).
  • •Specifically designed trial for elderly patients with advanced BC, in which both tumor response and the impact on MGA parameters were set as clinical end points for gemcitabine monochemotherapy.
  • Turkolmez K, Beduk Y, Baltaci S et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Ear. Urol. 44,682–686 (2003).
  • Sternberg CN, Calabro F, Pizzocaro G et aL Chemotherapy with an every-2 -week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based chemotherapy. Cancer 92,2993–2998 (2001).
  • Bellmunt J, Cos J, Cleries R et al. Feasibility trial of methotrexatepaclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 20,673–685 (2002).
  • Monfardini S. Evaluation of renal function in elderly cancer patients. Ann. Oncol. 15, 183–184 (2004).
  • Monfardini S, Perrone F. Should adjuvant chemotherapy be used to treat breast cancer in elderly patients70 years of age)?Eur. I Cancer33(11), 1723–1724 (1997).
  • Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97, S2083–52089 (2003).
  • Al-Sukhun S, Hussain M. Molecular biology of transitional cell carcinoma. Grit. Rev Oncol. Hernatol. 47,181–193 (2003).
  • Gontero P, Banisadr S, Frea B et al. Metastasis marker in bladder cancer: a review of the literature and clinical considerations. Eur. Uro1 46(3), 296–311 (2004).
  • Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Ear. J Cancer 37\(Suppl. 4), 9–15 (2001).
  • Philips G, Halabi S, Sanford D et al. Phase II trial of cisplatin, fixed dose rate of gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: preliminary results of CALGB 90102. Proc. Am. Soc. Clin. Oncol. 23,390 (2004) (Abstract 4540).
  • Hussain M, Smith DC, Vaishampayan U et al. Trastuzumab (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in patients with advanced urothelial cancer and overexpression of HER-2 (NCI study 198). Proc. Am. Soc. Clin. Oncol. 22,391 (2003) (Abstract 1569).
  • Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol. PathoL 54,215–221 (2001).
  • Kuban J, Wen SF, Leissner J et al. Successful adenovirus-mediated wild type p53 gene transfer in patients with bladder cancer by intra-vesical vector instillation. Clin. Oncol. 20,957-965 (2002).
  • Cote RJ, Datar RH. Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit. Rev arca Her-Rata 46, S67—S83 (2003).
  • •Detailed review on possible molecular targets for the design of new drugs against BC.

Websites

  • Cancer Statistics Review 1973–1999 http://seer.cancer.gov/csr/1973_1999/ bladder. pdf (Accessed November 2004).
  • University of Padua: Venetian Tumor Registry www.unipd.it/regtumve/altro/age.pdf (Accessed November 2004).
  • NCCN Clinical Practice Guidelines in OncologyTm www.nccn.org/physician_gls/f_guidelines.html (Accessed November 2004).
  • National Cancer Institute: Bladder Cancer (PDQM Treatment www.cancer.gov/cancertopics/pdq/treatmen t/bladder/healthprofessional/pagel (Accessed November 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.